Febuxostat, a non-purine selective inhibitor of xanthine oxidase effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety.

被引：0
|
作者：
Khosravan, R [1 ]
Mayer, M [1 ]
Grabowski, B [1 ]
Vernillet, L [1 ]
Wu, JT [1 ]
Joseph-Ridge, N [1 ]
机构：
[1] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S337 / S337
页数：1
相关论文
共 50 条
  • [31] No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor
    Wåhlander, K
    Eriksson-Lepkowska, M
    Frison, L
    Fager, G
    Eriksson, UG
    [J]. CLINICAL PHARMACOKINETICS, 2003, 42 (08) : 755 - 764
  • [32] No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor
    Karin Wåhlander
    Maria Eriksson-Lepkowska
    Lars Frison
    Gunnar Fager
    Ulf G. Eriksson
    [J]. Clinical Pharmacokinetics, 2003, 42 (8) : 755 - 764
  • [33] 3,5,2′,4′-Tetrahydroxychalcone, a new non-purine xanthine oxidase inhibitor
    Niu, Yanfen
    Zhu, Huajie
    Liu, Jia
    Fan, Huafang
    Sun, Ling
    Lu, Wei
    Liu, Xu
    Li, Ling
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2011, 189 (03) : 161 - 166
  • [34] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S843 - S843
  • [35] EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS
    Zahir, H.
    Lasseter, K.
    Marbury, T.
    Rondon, J.
    Bermudez, Y.
    Gammon, G.
    Kamel, Y. Mostafa
    Said, N.
    Hsu, C.
    Abutarif, M.
    Zheng, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S20 - S20
  • [36] Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
    Kletzl, Heidemarie
    Ajmi, Hassan
    Antys, Izabela
    Heinig, Katja
    Jaber, Birgit
    Marbury, Thomas C.
    Young, Annie
    Gunther, Andreas
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3749 - 3759
  • [37] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 976 - 976
  • [38] Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment
    Venkatakrishnan, Karthik
    Liu, Yi
    Noe, Dennis
    Mertz, Jaime
    Bargfrede, Michael
    Marbury, Thomas
    Farbakhsh, Kambiz
    Oliva, Cristina
    Milton, Ashley
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (06) : 998 - 1010
  • [39] Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a Phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia.
    Kamatani, N
    Fujimori, S
    Hada, T
    Hosoya, T
    Matsuzawa, Y
    Ueda, J
    Yamanaka, H
    Kato, R
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S337 - S337
  • [40] An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib
    Magee, Mindy He
    Shearn, Shawn
    Shaddinger, Bonnie
    Fang, Zixing
    Glaser, Ruchira
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 1014 - 1021
12345